A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939 on ClinicalTrials.gov · last registry update 2026-01-08

Finished 6 December 2022, after enrolling 120 people. Primary outcome, as filed: Part 1: Number of Treatment-emergent Adverse Events (TEAEs). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 120
Started: 2021-07-15
Primary completion: 2022-12-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Part 1: Number of Treatment-emergent Adverse Events (TEAEs)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.